Himatsingka Seide Limited
Valuation (90/100) does the heavy lifting; financial trend (4/100) is the drag.
Buy zoneSolvency riskHimatsingka Seide Limited earns a Sell from StocksWizard, with a blended score of 33/100. We put fair value near ₹158.46; at ₹79.23 that leaves roughly 100% upside, so the stock screens undervalued by 100%. On 17.9x trailing earnings it sits cheaper than the Consumer Cyclical median of about 27.7x. The price is about 43% below its 52-week high of ₹139.11 and 9% above the low of ₹72.64. Financial health scores 2/100, in the distress band on the Altman Z-score, with a Piotroski F-score of 5/9. The average analyst target of ₹182 implies about 130% upside across 2 analysts. It clears 2 of 13 investability checks, with durability 13, valuation 80 and momentum 8 on our 0–100 scales.
Analysis by Ankit Sharma · StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹126.77. Low-confidence estimate — limited data.
Analyst views
1-year price
EOD · 2026-07-3152-week range
-43.05% from the 52-week high.
Price above both moving averages reads as an intact uptrend; below both, the trend is against you.
Verdict pillars
Sell33Piotroski F-score 5/9 — quality of earnings & balance sheet.
Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Investability checklist
- Fail: ROE above 15%: 3.0%
- Fail: Low debt (D/E < 0.5): 1.23x
- Fail: Positive free cash flow
- Fail: Revenue growth > 10%: -6%
- Fail: Earnings growing: -88%
- Fail: Net margin ≥ 10%: 2.5%
- Fail: Current ratio > 1.5: 1.40
- Pass: Below our fair value
- Pass: Margin of safety ≥ 20%
- Fail: Above 200-day average
- Fail: Above 50-day average
- No data: Positive 1-year return
- Fail: Altman Z in safe zone: Z 1.08
- Fail: Piotroski ≥ 7: 5/9
Quarterly results
Annual financials
Shareholding
- Promoter43.5%
- Institutions12.1%
- Public & other44.4%
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
Bull case vs bear case
Bull case
Opportunities
- Trading in our value buy zone versus sector peers.
- Well off its 52-week high — possible mean-reversion.
- Trades ~100% below our estimated fair value.
Bear case
Weaknesses
- Low return on equity (3.0%).
- High debt relative to equity.
- Price below its 200-day moving average (downtrend).
Threats
- Earnings contracting year on year.
- Balance-sheet stress — Altman Z 1.08.
About Himatsingka Seide Limited
Himatsingka Seide Limited designs, manufactures, and distributes textile products including bedding, bath, yarn and fiber, and drapery and upholstery across North America, India, Asia Pacific, Europe, the Middle East, Africa, and other markets. The company operates multiple brands including Disney, Pixar, Marvel, and Star Wars licensed lines, as well as proprietary labels such as Pimacott, Organicott, Gizacott, Homegrown Cotton, and Bellora.
Himatsingka Seide Limited — frequently asked questions
Is Himatsingka Seide Limited a buy, hold or sell?
StocksWizard currently rates Himatsingka Seide Limited (HIMATSEIDE) a Sell, based on a blended score of 33/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.
What is Himatsingka Seide Limited's fair value?
Our blended DCF and relative-valuation model estimates Himatsingka Seide Limited's fair value at about ₹158.46, versus a current price of ₹79.23 — roughly 100% upside. On that basis the stock looks undervalued by 100%.
Is Himatsingka Seide Limited financially healthy?
Himatsingka Seide Limited scores 2/100 on our financial-health model, placing it in the distress band on the Altman Z-score, with a Piotroski F-score of 5/9.
How has Himatsingka Seide Limited's share price performed?
Himatsingka Seide Limited is down 9% over three months, and last traded at ₹79.23. Past performance doesn't predict future returns.
More in Consumer Cyclical
View allOur verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.